Silanes

Silanes, officially Laboratorios Silanes, is a longstanding Mexican pharmaceutical innovation company with a broad commercial portfolio spanning cardiometabolic disease, CNS, pain, respiratory medicine, vitamins, and antivenoms. The company states that it has more than 50 marketed products, operations reaching roughly 15 countries, and more than 150 patents accumulated over its history. In addition to conventional small-molecule pharmaceuticals and branded generics, Silanes develops biotechnological products based on antibodies and therapeutic peptides, and highlights capabilities in molecular biology, genomics, proteomics, and clinical development. A notable part of the group is its antivenom activity associated with Bioclon Silanes, which the company describes as world-leading in the research, development, and production of antivenoms for venomous bites and stings. The business also pursues in-licensing and business-development partnerships for late-stage or marketed products, particularly in CNS, diabetes, and respiratory disease.